Betamethasone is under clinical development by Surface Ophthalmics and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Betamethasone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Betamethasone overview

Betamethasone is under development for the treatment of episodic dry eye disease. It is administered by topical route in the form of eye drops. The drug candidate acts by targeting glucocorticoid receptor. It is formulated based on delivery vehicle Klarity drops technology.

Surface Ophthalmics overview

Surface Ophthalmics is a biopharmaceutical company that discovers, develops and commercializes therapeutics for ocular diseases. The company is headquartered in Pleasanton, California, the US.

For a complete picture of Betamethasone’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.